(Q36871990)

16 August 2017

1 reference

title

Novel therapeutic targets in mantle cell lymphoma (English)

1 reference

16 August 2017

Peter Martin

1

1 reference

16 August 2017

John P Leonard

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Therapeutic Targets

16 August 2017

published in

1 reference

16 August 2017

volume

11

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

929-940

1 reference

From the bench to the bedside: ways to improve rituximab efficacy.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Mechanism of active transcriptional repression by the retinoblastoma protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

The retinoblastoma protein and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Growth suppression by p16ink4 requires functional retinoblastoma protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Proteomic analysis of mantle-cell lymphoma by protein microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Endothelial cells in the bone marrow of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Thalidomide therapy induces response in relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

CDK4andMDM2Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-typeINK4a/ARFLocus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.7.929

10.1517/14728222.11.7.929

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference